Why Store NK Cells?

Why Store NK Cells?
Storing NK cells is a crucial step in safeguarding your future health
  • With the advancement of cell therapies, having stored, healthy NK cells will allow for effective treatment options when needed.
  • Young and active NK cells are key to successful therapies.
  • Storing your own cells eliminates concerns about immune rejection and side effects, ensuring that you have a personalized solution for potential future needs.
  • Immune cell storage is one of the best ways to prepare for battling cancer and various viral infections.
The faster you store NK cells, the more benefits you will have.
  • Research suggests that the proportion of cells responsible for NK cell activation decreases as we age, weakening our immune function.
  • Storing cells at a younger age ensures more effective future treatments.
Advanced and Safe NK Cell Cultivation and Storage
Simply separating and storing NK cells isn't enough for therapeutic use, as the cell count is too low
to achieve desired results. To ensure safe and effective immune cell therapy, it’s essential to have reliable cultivation technology. CHA Biotech leads the industry with cutting-edge NK cell cultivation methods, backed by 86 patents (as of May 2024), ensuring optimal safety and effectiveness.
Differentiated NK Cell Therapy
Immune cell therapy involves cultivating and activating immune cells, which are then administered through injections to boost the immune system. CHA Biotech provides this specialized NK cell therapy at its affiliated hospital, TCC Tokyo, utilizing advanced cultivation technologies.

World-Leading Cryopreservation Technology

  • Developed the world's first vitrification technology for egg freezing in 1998, with research featured in top medical textbooks such as Textbook of Assisted Reproductive Techniques (1998),
    Novak’s Gynecology (2002), and Fertility and Reproductive Medicine (1998)
  • Research achievements in infertility treatment were also featured in TIME magazine (1991, 1994)

Global Cell Therapy Development Network

  • CHA Biotech is driving forward immune therapy development and commercial-scale production through collaboration between Matica Biotechnology and the Texas A&M University CIADM program
  • By utilizing top-tier GMP expertise, the company ensures the highest product quality, creating a synergistic effect through the combined strengths of both institutions

Unique Technology and Premium Medical Services

  • Established patented NK cell cultivation technology to provide high-activity, high-quality NK cells
  • Cultivation facilities meet the strictest quality standards, ensuring top-tier cell products
TCC TOKYO Total Cell Clinic TOKYO

Global CHA Hospital Group Network

  • CHA Medical Group’s global presence spans seven countries, including the U.S., Korea, Australia, Japan, Singapore, Indonesia, and Vietnam, with a network of 91 medical centers worldwide

NK Cells and Enhanced Immunity

  • Ongoing research into NK cell therapies for COVID-19 is underway, with clinical trials being conducted globally (in collaboration with Celularity and other institutions)

Proven Safety and Efficacy

  • More than 6,311 treatments performed between September 2014 and December 2023,
    confirming both efficacy and safety
  • A 2017 study showed that 79.5% of patients experienced improvement or stabilization,
    with a twofold increase in the nine-year survival rate for lung cancer patients
  • Other findings demonstrated a 2.5 to 3-fold increase in survival time for patients with recurrent glioblastoma, extending their average survival from 6–8 months to 22.5 months
    (source: Bundang CHA Medical Center, Prof. Kyung-Gi Cho, PLoS ONE 16(3): e0247293)
  • Complete and partial remission in ovarian cancer patients, as presented by Prof. Won-Deok Joo
    at the 20th KGOG Meeting in NRG Oncology (2017)
  • Complete remission in liver cancer patients, presented by Prof. Joo-Ho Lee at the Korean Liver Cancer Association General Assembly (2020)
  • Additional research presented in August 2023 confirmed the safety and tolerability of combining transarterial chemoembolization (TACE) with immune cell therapy for liver cancer patients (lead researcher: Prof. Joo-Ho Lee)
NK Cell Therapy Process